HomeCompareCSPHF vs SPHD

CSPHF vs SPHD: Dividend Comparison 2026

CSPHF yields 198.02% · SPHD yields 4.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CSPHF wins by $112.67M in total portfolio value
10 years
CSPHF
CSPHF
● Live price
198.02%
Share price
$1.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$112.70M
Annual income
$56,534,499.65
Full CSPHF calculator →
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →

Portfolio growth — CSPHF vs SPHD

📍 CSPHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCSPHFSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CSPHF + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CSPHF pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CSPHF
Annual income on $10K today (after 15% tax)
$16,831.68/yr
After 10yr DRIP, annual income (after tax)
$48,054,324.70/yr
SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
At 15% tax rate, CSPHF beats the other by $48,053,839.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CSPHF + SPHD for your $10,000?

CSPHF: 50%SPHD: 50%
100% SPHD50/50100% CSPHF
Portfolio after 10yr
$56.36M
Annual income
$28,267,535.48/yr
Blended yield
50.15%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CSPHF buys
0
SPHD buys
0
No recent congressional trades found for CSPHF or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCSPHFSPHD
Forward yield198.02%4.33%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$112.70M$26.5K
Annual income after 10y$56,534,499.65$571.32
Total dividends collected$106.15M$5.1K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: CSPHF vs SPHD ($10,000, DRIP)

YearCSPHF PortfolioCSPHF Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$30,502$19,801.98$11,133$432.85+$19.4KCSPHF
2$89,086$56,448.56$12,363$450.36+$76.7KCSPHF
3$249,403$154,080.96$13,695$467.39+$235.7KCSPHF
4$670,003$403,142.26$15,138$483.90+$654.9KCSPHF
5$1,729,066$1,012,162.66$16,697$499.88+$1.71MCSPHF
6$4,291,289$2,441,188.37$18,382$515.31+$4.27MCSPHF
7$10,253,990$5,662,310.92$20,198$530.17+$10.23MCSPHF
8$23,616,660$12,644,890.45$22,157$544.46+$23.59MCSPHF
9$52,487,868$27,218,041.68$24,266$558.18+$52.46MCSPHF
10$112,696,518$56,534,499.65$26,536$571.32+$112.67MCSPHF

CSPHF vs SPHD: Complete Analysis 2026

CSPHFStock

CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor to treat hepatocellular carcinoma. Its products also comprise CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Shanghai, China.

Full CSPHF Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this CSPHF vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CSPHF vs SCHDCSPHF vs JEPICSPHF vs OCSPHF vs KOCSPHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.